Jane Yip

Autism Parent Care, LLC, United States

Jane Yip obtained her Ph.D. from the University of Newcastle, Australia, specializing in neuropharmacology. She has worked at Eli Lilly and Company, Indianapolis, USA and has a clinical practice that offers brain mapping and applied behavior analysis (ABA), Indiana Brain Mapping. Her research is on the brain circuit that underlies neurological disorders including depression, autism, and schizophrenia. Although trained in drug development, she has pioneered cutting-edge applications to the treatment of mental disorders from both neurobiology and behavioral science and uses natural environment modification as a treatment approach. She pioneered the use of portable brain imaging to guide behavior treatment for various mental disorders, including schizophrenia. As a member of ABAI and an NGO member of the United Nations, she works on outreach projects in Asia to advance the Universal Declaration of Human Rights, aiming to promote better recognition of individuals with mental disabilities, including schizophrenia. Her overarching aim to is advance treatment intervention, and apply innovative brain-mapping technology to help the public understand mental disorders.

Jane Yip

1books edited

1chapters authored

Latest work with IntechOpen by Jane Yip

Patients with schizophrenia need a personalized medicine approach where the pharmacological and neurological mechanism is understood from the perspective of the patient’s own experience and symptoms. Even though genetics play a role in the etiology, there are other important contributing risk factors. Schizophrenia is not a single-disease entity but has overlapping neurobiological and clinical profiles with other disorders such as autism and stress-related disorder. This expanded conceptualization benefits not only scholars but also diagnosing clinicians, as the diagnosis of schizophrenia is not always straightforward. The authors of this book discuss neurochemistry, animal models and antipsychotic models of schizophrenia to arrive at a personalized medicine approach for patients with schizophrenia. New treatment prospects from pharmacogenetic and neurotechnology research bring hope to clinicians and patients alike that, with continuing scientific studies, precisely targeted care is becoming available, with the potential of further alleviating the symptoms. Music therapy and patient-centered nursing practice are important aspects of clinical care as new directions are explored. This book will benefit researchers, clinicians, patients and family members needing a compact state-of-the-art reference resource. Knowledge is not only empowering but consoling, as our collective efforts to advance our understanding will translate into better treatment outcomes and the promise of a freer life for the patient.

Go to the book